(Reuters) - The FTSE 100 jumped on Monday after U.S. health regulators authorised a COVID-19 treatment over the weekend, while AstraZeneca boosted the index on a report the U.S. government was considering fast-tracking its experimental vaccine.
The British drugmaker gained 2.1% as the report said one option being explored would involve the U.S. health regulator awarding “emergency use authorisation” in October to the potential vaccine.
The export-laden FTSE 100 was up 1.7%, capping its best session in 12 days, while the mid-cap FTSE 250 rose 0.6%, led by financials and industrials.
“These are typical August markets where you don’t have a lot that’s driving them up except the absence of bad news,” said Michael Hewson, a market analyst at CMC Markets UK.
The blue-chip FTSE 100 has bounced from its March lows but lagged the U.S. benchmark S&P 500, which is scaling record highs on fiscal and monetary stimulus and hopes that the worst of the pandemic’s economic damage is over.
On Sunday, the U.S. Food & Drug Administration said it authorised the use of blood plasma from patients who had recovered from COVID-19 as a treatment for the disease.
“If last week was beset by the economic realities of the COVID-19 pandemic, then Monday is starting out with a (temporary) cure for those concerns,” said financial analyst Connor Campbell at spreadbetters Spreadex.
The focus will turn to U.S. Federal Reserve Chair Jerome Powell’s address at the Kansas City Fed’s annual conference on Thursday for any hints as to the central bank’s efforts to revamp its approach to monetary policy.
Bunzl Plc gained 2.8% after resuming dividends, while pub operator J D Wetherspoon fell 3% as its sales were still down sharply year-on-year despite the government’s subsidised meal scheme and calls for tax relief for the hospitality sector to be extended
Reporting by Sagarika Jaisinghani and Shreyashi Sanyal in Bengaluru; Editing by Subhranshu Sahu and Ken Ferris
Our Standards: The Thomson Reuters Trust Principles.